Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target Lowered to $37.00 at Morgan Stanley

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) had its price target dropped by Morgan Stanley from $40.00 to $37.00 in a report released on Thursday, Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Morgan Stanley’s target price would indicate a potential upside of 43.91% from the stock’s previous […]

Related Keywords

Canada ,United States ,Christopher Richard Anzalone ,Arrowhead Pharmaceuticals Company Profile ,Analyst Recommendations For Arrowhead Pharmaceuticals ,Arrowhead Pharmaceuticals ,Morgan Stanley ,Third Bancorp ,Insider Transactions At Arrowhead Pharmaceuticals ,Citigroup ,Fifth Third Bancorp ,News Ratings For Arrowhead Pharmaceuticals Daily ,Royal Bank ,Cantor Fitzgerald ,Advisors Asset Management Inc ,Hedge Funds Weigh In On Arrowhead Pharmaceuticals ,Star Investment Management Corp ,Arrowhead Pharmaceuticals Trading Down ,Securities Exchange Commission ,Arrowhead Pharmaceuticals Inc ,Get Free Report ,Pharmaceuticals Trading Down ,Martin Javier San ,Exchange Commission ,Richard Anzalone ,Star Investment Management ,Advisors Asset Management ,Asset Management ,Arrowhead Pharmaceuticals Daily ,Nasdaq Arwr ,Arwr ,Medical ,Lower Price Target ,